Additional file 1 of Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Supplementary Material 1. (Supplemental 1A.) TNBC cell lines from Fig. 1A with corresponding p53 mutation and doxorubicin IC50 value. All mutations were found on https://www.cellosaurus.org/. (Supplemental 1B) Pro-apoptotic effects of DOX in combination with OKI-005. Representative plots of Annexin V/ PI in the cell lines CAL-51, MDA-MB-231, Hs 578T, and CAL-120 cell lines after 24 hours of treatment with DOX (0.5 µM), OKI-005 (0.2 µM), or combination as measured by flow cytometry. Ordinary one-way ANOVA with Tukey correction comparing single agent to combination (* = p < 0.05, ** = P < 0.01). (Supplemental 1 C) Densitometry of cleaved caspase-3 quantified by ImageJ. Cleaved caspase-3 was normalized to no drug for each treatment group along with their corresponding loading control (actin). (Supplemental 1D) β-galactosidase expression quantified by measuring β-galactosidase pixel density with ImageJ. (Supplemental 2A) Net body weight for Fig. 5 in vivo xenograft study. (Supplemental 2B) qRT-PCR confirming adequate KD of p53 using TaqMan gene expression assay (Applied Biosystems). (Supplemental 2 C) Pro-apoptotic effects of DOX in combination with OKI-005. Representative plots of Annexin V/ PI in the cell lines CAL-51 SCR and CAL-51 P53-10 cell lines after 24 hours of treatment with DOX (0.5 µM), OKI-005 (0.2 µM), or combination as measured by flow cytometry. Ordinary one-way ANOVA with Tukey correction comparing single agent to combination (* = p < 0.05, *** = P < 0.001). (Supplemental 2D) Percent senescent cells in CAL-51 SCR and CAL-51 P53-10 after 6-days drug treatment. Three independent fields were hand counted and the percentage was calculated based off total cells present